Press Releases Capricor Therapeutics, Inc.

Equities

CAPR

US14070B3096

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
6.2 ^USD	+9.93%		+14.39%	+26.79%

May. 17	Oppenheimer Initiates Capricor Therapeutics at Outperform Rating	MT
May. 13	Transcript : Capricor Therapeutics, Inc., Q1 2024 Earnings Call, May 13, 2024

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Capricor: Q1 Earnings Snapshot	May. 13	AQ
Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update	May. 13	AQ
Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting	May. 09	AQ
Capricor Therapeutics to Present at Upcoming Scientific and Medical Conferences	May. 08	AQ
Capricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13	May. 06	AQ
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy	Apr. 24	AQ
Capricor Therapeutics to Present at Upcoming Investor Conferences	Mar. 21	AQ
Capricor Therapeutics Presents at 2024 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference	Mar. 06	AQ
Capricor: Q4 Earnings Snapshot	Feb. 29	AQ
Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	Feb. 29	AQ
Capricor Therapeutics Announces Upcoming Type-B Meeting with the FDA to Discuss Commercial Manufacturing Planning with an Aim to Expedite BLA Pathway for CAP-1002 in Duchenne Muscular Dystrophy	Feb. 27	AQ
Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29	Feb. 22	AQ
Capricor Therapeutics Announces Manufacturing Scale-Up of CAP-1002 Production at New San Diego Facility as it Continues Plans Toward Commercialization	Feb. 20	AQ
Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine for SARS-CoV-2	Jan. 24	AQ
Capricor Therapeutics Announces Continuation of Phase 3 HOPE-3 Trial of CAP-1002 in Duchenne Muscular Dystrophy Based on Completion of Interim Futility Analysis	Dec. 11	AQ
Capricor: Q3 Earnings Snapshot	Nov. 14	AQ
Capricor Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update	Nov. 14	AQ
Brain Hemorrhage Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	Nov. 14	AQ
Capricor Therapeutics to Present Third Quarter 2023 Financial Results and Recent Corporate Update on November 14	Nov. 07	AQ
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments of CAP-1002 Program	23-10-19	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Capricor Therapeutics, Inc.

Equities

CAPR

US14070B3096

Press Releases

Filters